| scholarly article | Q13442814 |
| P356 | DOI | 10.1111/BCP.12334 |
| P8608 | Fatcat ID | release_scyndlpv2nfkvpl2iq6vj6ma5u |
| P932 | PMC publication ID | 4137821 |
| P698 | PubMed publication ID | 25099256 |
| P2093 | author name string | Jaymin B Morjaria | |
| K Suresh Babu | |||
| Jack A Kastelik | |||
| P2860 | cites work | Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial | Q44313160 |
| Chronic respiratory disease, inhaled corticosteroids and risk of non-tuberculous mycobacteriosis | Q44315081 | ||
| Health status and the spiral of decline | Q44368782 | ||
| Long-term effects of budesonide on inflammatory status in COPD. | Q44398976 | ||
| The efficacy and safety of fluticasone propionate (250 microg)/salmeterol (50 microg) combined in the Diskus inhaler for the treatment of COPD. | Q44582263 | ||
| Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease | Q44696559 | ||
| Effects of fluticasone on systemic markers of inflammation in chronic obstructive pulmonary disease | Q44960162 | ||
| Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials. | Q45939644 | ||
| Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results. | Q46011452 | ||
| The effect of inhaled corticosteroids on the development of emphysema in smokers assessed by annual computed tomography. | Q46045096 | ||
| Fluticasone and N-acetylcysteine in primary care patients with COPD or chronic bronchitis | Q46166429 | ||
| Anti-inflammatory effects of combined budesonide/formoterol in COPD exacerbations | Q46274712 | ||
| Risk for death associated with medications for recently diagnosed chronic obstructive pulmonary disease | Q46365320 | ||
| Medications to modify lung function decline in chronic obstructive pulmonary disease: some hopeful signs | Q46448011 | ||
| Long-term mortality follow-up of the ISOLDE participants: causes of death during 13 years after trial completion | Q46487950 | ||
| Effects of inhaled HFA beclomethasone on pulmonary function and symptoms in patients with chronic obstructive pulmonary disease | Q46491099 | ||
| Effect of fluticasone propionate/salmeterol (250/50 microg) or salmeterol (50 microg) on COPD exacerbations | Q46493029 | ||
| The effect of inhaled corticosteroids on bronchoalveolar lavage cells and IL-8 levels in stable COPD patients | Q46537353 | ||
| Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study | Q46568144 | ||
| The effects of fluticasone with or without salmeterol on systemic biomarkers of inflammation in chronic obstructive pulmonary disease | Q46725792 | ||
| Antiinflammatory effects of salmeterol/fluticasone propionate in chronic obstructive lung disease | Q46902397 | ||
| The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide | Q46966092 | ||
| Factors affecting survival of hospitalised patients with COPD. | Q47754437 | ||
| Surprisingly high prevalence of anxiety and depression in chronic breathing disorders | Q47817340 | ||
| Impact of salmeterol/fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease | Q48487432 | ||
| Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease. | Q49083880 | ||
| Steroid reversibility test followed by inhaled budesonide or placebo in outpatients with stable chronic obstructive pulmonary disease. The Danish Society of Respiratory Medicine. | Q50565055 | ||
| Eosinophilic airway inflammation and exacerbations of COPD: a randomised controlled trial. | Q50697152 | ||
| Inhaled corticosteroids and hip fracture: a population-based case-control study. | Q50709815 | ||
| Efficacy and safety of inhaled corticosteroids in patients with COPD: a systematic review and meta-analysis of health outcomes | Q22306079 | ||
| Combined corticosteroid and long-acting beta(2)-agonist in one inhaler versus long-acting beta(2)-agonists for chronic obstructive pulmonary disease | Q24200446 | ||
| Inhaled corticosteroids for stable chronic obstructive pulmonary disease | Q24202092 | ||
| Inhaled corticosteroids versus long-acting beta2-agonists for chronic obstructive pulmonary disease | Q24234164 | ||
| Inhaled corticosteroids versus long-acting beta 2 -agonists for chronic obstructive pulmonary disease | Q24236037 | ||
| Combined corticosteroid and long-acting beta-agonist in one inhaler versus placebo for chronic obstructive pulmonary disease | Q24243564 | ||
| Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial | Q24642534 | ||
| Oxygen therapy in chronic obstructive pulmonary disease | Q24650725 | ||
| The natural history of chronic airflow obstruction | Q24674578 | ||
| Effects of inhaled corticosteroids on sputum cell counts in stable chronic obstructive pulmonary disease: a systematic review and a meta-analysis | Q24797765 | ||
| Health-related quality of life is related to COPD disease severity | Q24814864 | ||
| The MOS 36-ltem Short-Form Health Survey (SF-36) | Q26778425 | ||
| Aerosolized beclomethasone in chronic bronchitis. Improved pulmonary function and diminished airway inflammation | Q28318173 | ||
| Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society | Q29616361 | ||
| Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease | Q29618681 | ||
| The nature of small-airway obstruction in chronic obstructive pulmonary disease | Q29618682 | ||
| Respiratory symptoms in adults are related to impaired quality of life, regardless of asthma and COPD: results from the European community respiratory health survey | Q30496983 | ||
| Budesonide and the risk of pneumonia: a meta-analysis of individual patient data | Q33498280 | ||
| Burden of COPD in a government health care system: a retrospective observational study using data from the US Veterans Affairs population | Q33575949 | ||
| Systemic adverse effects of inhaled corticosteroid therapy: A systematic review and meta-analysis | Q33634936 | ||
| Airways obstruction, chronic expectoration, and rapid decline of FEV1 in smokers are associated with increased levels of sputum neutrophils | Q33775871 | ||
| Inhaled corticosteroids, family history, and risk of glaucoma | Q33795569 | ||
| Mega trials in COPD--clinical data analysis and design issues. | Q33878625 | ||
| Influencing the decline of lung function in COPD: use of pharmacotherapy | Q33966001 | ||
| An overview of the benefits and drawbacks of inhaled corticosteroids in chronic obstructive pulmonary disease | Q34065958 | ||
| Up-to-date on mortality in COPD - report from the OLIN COPD study | Q34122162 | ||
| Characterisation of COPD heterogeneity in the ECLIPSE cohort | Q34149510 | ||
| Cellular and structural bases of chronic obstructive pulmonary disease | Q34260279 | ||
| Persistent systemic inflammation is associated with poor clinical outcomes in COPD: a novel phenotype | Q34280020 | ||
| The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial | Q34394365 | ||
| Inhaled corticosteroid effects on bone metabolism in asthma and mild chronic obstructive pulmonary disease | Q34547011 | ||
| Impact of preventing exacerbations on deterioration of health status in COPD. | Q34548347 | ||
| The association of inhaled corticosteroid use with serum glucose concentration in a large cohort | Q34606671 | ||
| Inhaled Corticosteroids and the Risks of Diabetes Onset and Progression | Q34623808 | ||
| Risk of new onset diabetes mellitus in patients with asthma or COPD taking inhaled corticosteroids | Q34641576 | ||
| The effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a systematic review of randomized placebo-controlled trials | Q34727099 | ||
| Inhaled and nasal glucocorticoids and the risks of ocular hypertension or open-angle glaucoma | Q34738227 | ||
| Inhaled corticosteroids in patients with stable chronic obstructive pulmonary disease: a systematic review and meta-analysis | Q34888769 | ||
| Dose-response relationship of inhaled corticosteroids and cataracts: a systematic review and meta-analysis. | Q35001815 | ||
| Randomised controlled trial of inhaled corticosteroids in patients with chronic obstructive pulmonary disease | Q35532488 | ||
| Long term effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a meta-analysis. | Q35532769 | ||
| Development of a self-reported Chronic Respiratory Questionnaire (CRQ-SR). | Q35534329 | ||
| Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease | Q35534824 | ||
| Effects of fluticasone propionate in COPD patients with bronchial hyperresponsiveness | Q35535306 | ||
| Inhaled corticosteroids reduce the progression of airflow limitation in chronic obstructive pulmonary disease: a meta-analysis | Q35535545 | ||
| Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis | Q35536791 | ||
| Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. | Q35537270 | ||
| Inhaled corticosteroids and mortality in chronic obstructive pulmonary disease | Q35537366 | ||
| Sputum eosinophilia and the short term response to inhaled mometasone in chronic obstructive pulmonary disease. | Q35537515 | ||
| Withdrawal of fluticasone propionate from combined salmeterol/fluticasone treatment in patients with COPD causes immediate and sustained disease deterioration: a randomised controlled trial | Q35537740 | ||
| Decline in lung function and mortality: the Busselton Health Study | Q35558834 | ||
| Corticosteroid resistance in chronic obstructive pulmonary disease: inactivation of histone deacetylase. | Q35682823 | ||
| Cost-effectiveness of available treatment options for patients suffering from severe COPD in the UK: a fully incremental analysis. | Q35885176 | ||
| A population based case-control study of cataract and inhaled corticosteroids | Q35895189 | ||
| Blood eosinophils to direct corticosteroid treatment of exacerbations of chronic obstructive pulmonary disease: a randomized placebo-controlled trial | Q36105874 | ||
| Effect of salmeterol/fluticasone propionate on airway inflammation in COPD: a randomised controlled trial | Q36225454 | ||
| Safety of inhaled corticosteroids | Q36236845 | ||
| Effects of inhaled corticosteroids on airway inflammation in chronic obstructive pulmonary disease: a systematic review and meta-analysis | Q36283909 | ||
| Statistical treatment of exacerbations in therapeutic trials of chronic obstructive pulmonary disease | Q36378698 | ||
| Withdrawal of inhaled corticosteroids in people with COPD in primary care: a randomised controlled trial | Q36464679 | ||
| The burden of COPD in the U.K.: results from the Confronting COPD survey. | Q50716197 | ||
| Association of inhaled corticosteroid use with cataract extraction in elderly patients. | Q50870339 | ||
| The influence of COPD on health-related quality of life independent of the influence of comorbidity. | Q51944756 | ||
| Inhaled steroids and mortality in COPD: bias from unaccounted immortal time. | Q52961320 | ||
| Observational studies of inhaled corticosteroids in chronic obstructive pulmonary disease: misconstrued immortal time bias. | Q52998778 | ||
| Quality of life measured by the St George's Respiratory Questionnaire and spirometry. | Q53117439 | ||
| Multicentre randomised placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease. International COPD Study Group. | Q53355524 | ||
| Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. | Q53577143 | ||
| Quality of life, symptoms and pulmonary function in asthma: long-term treatment with nedocromil sodium examined in a controlled multicentre trial. Nedocromil Sodium Quality of Life Study Group. | Q53670194 | ||
| Decreased histone deacetylase activity in chronic obstructive pulmonary disease. | Q54664094 | ||
| Use of inhaled corticosteroids and the risk of tuberculosis | Q57213532 | ||
| Prevention of Death in COPD | Q57559761 | ||
| Chronic obstructive pulmonary disease in patients admitted with heart failure | Q57955879 | ||
| Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial | Q57956059 | ||
| Lung Function Decline and Outcomes in an Adult Population | Q58061976 | ||
| Complex chronic comorbidities of COPD | Q58877111 | ||
| Effect of High Dose Inhaled Steroid on Cells, Cytokines, and Proteases in Induced Sputum in Chronic Obstructive Pulmonary Disease | Q60695425 | ||
| Health Status Deterioration in Patients with Chronic Obstructive Pulmonary Disease | Q61862817 | ||
| The St George's Respiratory Questionnaire | Q67797390 | ||
| Effects of long-term treatment with corticosteroids in COPD | Q71068374 | ||
| Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial. Nocturnal Oxygen Therapy Trial Group | Q71522922 | ||
| Hospital and 1-year survival of patients admitted to intensive care units with acute exacerbation of chronic obstructive pulmonary disease | Q71588560 | ||
| Changes in dyspnea, health status, and lung function in chronic airway disease | Q72387414 | ||
| Effects of inhaled and oral glucocorticoids on inflammatory indices in asthma and COPD | Q73071104 | ||
| Inflammation in bronchial biopsies of subjects with chronic bronchitis: inverse relationship of CD8+ T lymphocytes with FEV1 | Q73263338 | ||
| Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease | Q73341072 | ||
| Comparison of induced sputum with bronchial wash, bronchoalveolar lavage and bronchial biopsies in COPD | Q73457516 | ||
| Inflammatory cells in the bronchial glands of smokers with chronic bronchitis | Q73885941 | ||
| CD8+ T-lymphocytes in peripheral airways of smokers with chronic obstructive pulmonary disease | Q74363422 | ||
| Inhaled corticosteroids and the risk of mortality and readmission in elderly patients with chronic obstructive pulmonary disease | Q74420326 | ||
| Fracture risk associated with inhaled corticosteroid use in chronic obstructive pulmonary disease | Q75230554 | ||
| Inhaled corticosteroids with/without long-acting beta-agonists reduce the risk of rehospitalization and death in COPD patients | Q75252022 | ||
| Inhaled corticosteroids in chronic obstructive pulmonary disease and risk of death and hospitalization: time-dependent analysis | Q79116899 | ||
| Patient understanding, detection, and experience of COPD exacerbations: an observational, interview-based study | Q79902627 | ||
| Inhaled corticosteroid use in chronic obstructive pulmonary disease and the risk of hospitalization for pneumonia | Q80076108 | ||
| Inhaled corticosteroids and mortality in COPD | Q80237255 | ||
| Low-dose inhaled corticosteroids and the risk of acute myocardial infarction in COPD | Q81599593 | ||
| Inhaled corticosteroids are more effective in COPD patients when used with LABA than with SABA | Q81793878 | ||
| Impact of inhaled corticosteroid use on outcome in COPD patients admitted with pneumonia | Q83690965 | ||
| Inhaled corticosteroids and risk of tuberculosis in patients with respiratory diseases | Q85123914 | ||
| Cost-effectiveness of roflumilast in combination with bronchodilator therapies in patients with severe and very severe COPD in Switzerland | Q36584673 | ||
| Pneumonia and pneumonia related mortality in patients with COPD treated with fixed combinations of inhaled corticosteroid and long acting β2 agonist: observational matched cohort study (PATHOS) | Q36883006 | ||
| Counting, analysing and reporting exacerbations of COPD in randomised controlled trials. | Q36912026 | ||
| Immortal time bias in pharmaco-epidemiology | Q37023172 | ||
| Assessing treatment effects of inhaled corticosteroids on medical expenses and exacerbations among COPD patients: longitudinal analysis of managed care claims. | Q37037387 | ||
| Methodological issues in therapeutic trials of COPD. | Q37063828 | ||
| Economic burden in direct costs of concomitant chronic obstructive pulmonary disease and asthma in a Medicare Advantage population | Q37106430 | ||
| Exacerbation rate, health status and mortality in COPD--a review of potential interventions | Q37236165 | ||
| Inhaled corticosteroids in COPD and the risk of serious pneumonia | Q37267655 | ||
| Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH study | Q37271761 | ||
| Long-term use of inhaled corticosteroids and the risk of pneumonia in chronic obstructive pulmonary disease: a meta-analysis | Q37388939 | ||
| Systemic manifestations and comorbidities of COPD. | Q37465879 | ||
| Safety and efficacy of combined long-acting beta-agonists and inhaled corticosteroids vs long-acting beta-agonists monotherapy for stable COPD: a systematic review. | Q37562626 | ||
| Inhaled corticosteroids vs placebo for preventing COPD exacerbations: a systematic review and metaregression of randomized controlled trials | Q37604109 | ||
| Risk of myocardial infarction and cardiovascular death associated with inhaled corticosteroids in COPD. | Q37635594 | ||
| Inhaled corticosteroids in chronic obstructive pulmonary disease: a review. | Q37681569 | ||
| Risk of fractures with inhaled corticosteroids in COPD: systematic review and meta-analysis of randomised controlled trials and observational studies | Q37878200 | ||
| Bronchoscopic interventions in the management of chronic obstructive pulmonary disease | Q38073552 | ||
| Use of inhaled corticosteroids and the risk of cataracts. | Q39448051 | ||
| Chronic obstructive pulmonary disease lost in translation: Why are the inhaled corticosteroids skeptics refusing to go? | Q39461476 | ||
| Sputum eosinophilia predicts benefit from prednisone in smokers with chronic obstructive bronchitis | Q40835380 | ||
| European Respiratory Society study on chronic obstructive pulmonary disease (EUROSCOP): hypothesis and design | Q41106558 | ||
| Effect of an inhaled glucocorticoid on reactive oxygen species production by bronchoalveolar lavage cells from smoking COPD patients | Q41977808 | ||
| Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial | Q42612610 | ||
| Beclomethasone/formoterol in the management of COPD: a randomised controlled trial | Q42851090 | ||
| Effect of fluticasone propionate/salmeterol (250/50) on COPD exacerbations and impact on patient outcomes | Q43253466 | ||
| Effect of fluticasone with and without salmeterol on pulmonary outcomes in chronic obstructive pulmonary disease: a randomized trial | Q43258577 | ||
| Mortality in the 4-year trial of tiotropium (UPLIFT) in patients with chronic obstructive pulmonary disease | Q43281145 | ||
| The risk of cataract among users of inhaled steroids | Q43541134 | ||
| Primary care burden and treatment of patients with heart failure and chronic obstructive pulmonary disease in Scotland | Q43792082 | ||
| Bone mineral density in patients with chronic obstructive pulmonary disease treated with budesonide Turbuhaler | Q43913522 | ||
| The effects of inhaled fluticasone on airway inflammation in chronic obstructive pulmonary disease: a double-blind, placebo-controlled biopsy study | Q44031728 | ||
| Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease | Q44179168 | ||
| Survival in COPD patients after regular use of fluticasone propionate and salmeterol in general practice | Q44202398 | ||
| Effect of budesonide/formoterol pMDI on COPD exacerbations: a double-blind, randomized study | Q44256287 | ||
| Determinants of depression in the ECLIPSE chronic obstructive pulmonary disease cohort | Q44282710 | ||
| Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease | Q44304480 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | chronic obstructive pulmonary disease | Q199804 |
| P304 | page(s) | 282-300 | |
| P577 | publication date | 2014-08-01 | |
| P1433 | published in | British Journal of Clinical Pharmacology | Q176044 |
| P1476 | title | Inhaled corticosteroids in chronic obstructive pulmonary disease: a pro-con perspective | |
| P478 | volume | 78 |
| Q47836122 | A 6-alkylsalicylate histone acetyltransferase inhibitor inhibits histone acetylation and pro-inflammatory gene expression in murine precision-cut lung slices |
| Q36332206 | Applying the wisdom of stepping down inhaled corticosteroids in patients with COPD: a proposed algorithm for clinical practice |
| Q91686040 | Blood eosinophils and treatment response with triple and dual combination therapy in chronic obstructive pulmonary disease: analysis of the IMPACT trial |
| Q57022975 | Concomitant inhaled corticosteroid use and the risk of pneumonia in COPD: a matched-subgroup post hoc analysis of the UPLIFT® trial |
| Q38541928 | Developments in inhaled combination therapies: patent activity 2013-2014. |
| Q26828976 | Excess costs of comorbidities in chronic obstructive pulmonary disease: a systematic review |
| Q37721580 | HDAC1-3 inhibitor MS-275 enhances IL10 expression in RAW264.7 macrophages and reduces cigarette smoke-induced airway inflammation in mice |
| Q33705358 | Inhaled Corticosteroid use and the Risk of Pneumonia and COPD Exacerbations in the UPLIFT Study |
| Q91695118 | Inhaled corticosteroids and FEV1 decline in chronic obstructive pulmonary disease: a systematic review |
| Q64935622 | Inhaled corticosteroids, blood eosinophils, and FEV1 decline in patients with COPD in a large UK primary health care setting. |
| Q47661714 | Inhaled therapies in patients with moderate COPD in clinical practice: current thinking. |
| Q26825822 | Profile of inhaled glycopyrronium bromide as monotherapy and in fixed-dose combination with indacaterol maleate for the treatment of COPD |
| Q39032379 | Single-Center Retrospective Evaluation of Inhaled Corticosteroid Use for Chronic Obstructive Pulmonary Disease Exacerbation Patients Receiving Systemic Corticosteroids. |
| Q57712790 | Targeting transcription factor lysine acetylation in inflammatory airway diseases |
| Q47718704 | Use of ICS in COPD: From Blockbuster Medicine to Precision Medicine |
Search more.